The University of Southampton
University of Southampton Institutional Repository

Donepezil in vascular dementia: a randomized, placebo-controlled study

Wilkinson, D., Doody, R., Helme, R., Taubman, K., Mintzer, J, Kertesz, A. and Pratt, R.D., Donepezil 308 Study Group Donepezil 308 Study Group (2003) Donepezil in vascular dementia: a randomized, placebo-controlled study Neurology, 61, (4), pp. 479-486.

Record type: Article

Abstract

Objective: To evaluate the efficacy and tolerability of donepezil in patients with vascular dementia (VaD).
Methods: Patients (n = 616; mean age, 75.0 years) with probable or possible VaD, according to National Institute of Neurological Disorders and Stroke–Association Internationale pour la Recherche en l’Enseignement en Neurosciences criteria, were randomized to receive donepezil 5 mg/day (n = 208), donepezil 10 mg/day (after 5 mg/day for the first 28 days) (n = 215), or placebo (n = 193) for 24 weeks.
Results: Seventy-six percent of the patients enrolled had probable VaD. A total of 75.3% of the 10 mg donepezil group and 80.8% of the 5 mg group completed the study compared with 83.4% of the placebo group. Both donepezil-treated groups showed improvements in cognitive function on the Alzheimer’s Disease Assessment Scale–cognitive subscale compared with placebo, with a mean endpoint treatment difference, as measured by the change from baseline score, of approximately 2 points (donepezil 5 mg, -1.65 [p = 0.003]; 10 mg, -2.09 [p = 0.0002]). Greater improvements on the Clinician’s Interview-Based Impression of Change–plus version were observed with both donepezil groups than with the placebo group (overall donepezil treatment vs placebo p = 0.008); 25% of the placebo group showed improvement compared with 39% (p = 0.004) of the 5 mg group and 32% (p = 0.047) of the 10 mg group. Withdrawal rates due to adverse events were low (placebo, 8.8%; donepezil 5 mg, 10.1%; 10 mg, 16.3%).
Conclusions: Donepezil-treated patients demonstrated significant improvements in cognition and global function compared with placebo-treated patients, and donepezil was well tolerated.

PDF 00006114-200308260-00013.pdf - Version of Record
Restricted to Repository staff only
Download (175kB)

More information

Published date: August 2003

Identifiers

Local EPrints ID: 40737
URI: http://eprints.soton.ac.uk/id/eprint/40737
ISSN: 0028-3878
PURE UUID: 588cc707-b07d-46b3-b068-4dca6f76ad89

Catalogue record

Date deposited: 07 Jul 2006
Last modified: 17 Jul 2017 15:33

Export record

Contributors

Author: D. Wilkinson
Author: R. Doody
Author: R. Helme
Author: K. Taubman
Author: J Mintzer
Author: A. Kertesz
Author: R.D., Donepezil 308 Study Group Pratt

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×